What do billion-dollar biotech deals and Stephen Curry’s impostor syndrome have in common?
Hosted by Michelle Martin with Ryan Huang, today’s Market View kicks off with two major cancer-fighting pharmaceutical deals—Bristol Myers Squibb teams up with BioNTech while Sanofi acquires Blueprint Medicines.
We dive into why Tung Lok’s profits have halved, despite Singapore’s food scene buzzing with new openings and closings.
We look at Grab entering the motor insurance industry and later, Nio, CK Hutchison, and Stamford Land take center stage in our corporate UP or DOWN round-up.
Plus, we look at STI movers like DFI Retail, Jardine Matheson, and SGX.
And in a surprising twist, NBA star Stephen Curry reveals he still battles impostor syndrome—yes, even champions have doubts.
Companies mentioned: Bristol Myers Squibb, BioNTech, Sanofi, Blueprint Medicines, Tung Lok, Nio, Stamford Land, CK Hutchison, Vodafone, Jardine Matheson, SGX, DFI Retail.

Market View: AI Spending Jitters Shake Wall Street as Allianz Bets on Singapore
14:53

Money and Me: Finding Alpha Beyond the Blue Chips: 4 Singapore Small-Cap Stocks in Focus
22:02

Market View: SpaceX, Grab and Sea Arrive on SGX as AI Powers Wall Street Higher
15:00